加载中
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
前收盘价
US$76.39
+US$0.48 · +0.63%
盘中时间采用ET。市场数据可能有所延迟。
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
日内区间
当前US$76.39
52周区间
当前US$76.39
盘中时间采用ET。市场数据可能有所延迟。
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
日内区间
当前US$76.39
52周区间
当前US$76.39
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 13.88亿 USD | 12.53亿 USD | 11.54亿 USD | 10.22亿 USD | 10.35亿 USD |
| 销货成本 | 4.48亿 USD | 3.83亿 USD | 3.82亿 USD | 3.15亿 USD | 3.29亿 USD |
| 毛利 | 9.4亿 USD | 8.71亿 USD | 7.71亿 USD | 7.07亿 USD | 7.06亿 USD |
| 研究与开发 | 1.86亿 USD | 1.83亿 USD | 1.94亿 USD | 1.56亿 USD | 1.83亿 USD |
| 销售、一般及管理费用 | 5.49亿 USD | 5.26亿 USD | 5.18亿 USD | 4.69亿 USD | 4.72亿 USD |
| 营业费用 | 7.41亿 USD | 7.42亿 USD | 8.4亿 USD | 7.84亿 USD | 7.07亿 USD |
| 利息收入 | 1898.2万 USD | 3007.5万 USD | 2201.2万 USD | 469.7万 USD | 43.5万 USD |
| 利息支出 | 4928.6万 USD | 6307万 USD | 5885.3万 USD | 4825万 USD | 5015.1万 USD |
| 折旧和摊销 | 4200万 USD | 5114.4万 USD | 6085.6万 USD | 5779.6万 USD | 6798.8万 USD |
| 营业利润 | 1.99亿 USD | 1.29亿 USD | −6849.8万 USD | −7675.2万 USD | −78.4万 USD |
| 净利润 | −2.43亿 USD | 6323.4万 USD | 1754.6万 USD | −8624.6万 USD | −1.36亿 USD |
公司数据更新于 2026年10月11日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$93.33
上涨空间 22.18%价格历史记录不可用
最高：US$105平均的：US$93.33最低：US$85.00报告持有此股票敞口的交易所交易基金。
Avantis U.S. Small Cap Value ETFAVUV1.22亿0.39%308.51亿 USD0.25%US$119.64-0.41%
iShares Russell 2000 ETFIWM1.12亿0.14%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF5094.27万0.05%954亿 USD0.05%US$235+0.80%
Dimensional - US Targeted Value ETFDFAT3996.29万0.13%301.22亿 USD0.33%US$67.27-0.43%
Invesco S&P MidCap Momentum ETFXMMO3499.43万0.49%71.38亿 USD0.34%US$148.79+0.96%
Dimensional - US Small Cap ETFDFAS3213.03万0.10%338.69亿 USD0.31%US$78.35+0.32%
Invesco S&P MidCap Quality ETFXMHQ3156.12万0.58%54.37亿 USD0.30%US$114.23+0.50%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY3135.6万0.12%258.17亿 USD0.23%US$669.87+0.54%Avantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Targeted Value ETFDFATInvesco S&P MidCap Momentum ETFXMMODimensional - US Small Cap ETFDFASInvesco S&P MidCap Quality ETFXMHQState Street SPDR S&P MIDCAP 400 ETF TrustMDYAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
